At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 201 enrolled
Drug / intervention
pilocarpine hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilocarpine for Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study
In Brief
A Phase 3 clinical trial evaluating pilocarpine hydrochloride and placebo for Breast Cancer and Vaginal Dryness. Completed, enrolled 201 participants across 192 sites.
Detailed Summary
RATIONALE: Pilocarpine may decrease vaginal dryness and improve quality of life in patients with breast cancer It is not yet known whether pilocarpine is more effective than a placebo in treating vaginal dryness in patients with breast cancer. PURPOSE: This randomized phase III trial is studying pilocarpine to see how well it works compared to a placebo in treating vaginal dryness in patients with breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Vaginal Dryness
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2006
Enrollment StartDec 2006
Primary CompletionJul 2009
Study CompletionDec 2012
TodayJul 2026
First PostedJun 23, 2006
Enrollment StartDec 1, 2006
Primary CompletionJul 1, 2009
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.0 years ago
Interventions
pilocarpine hydrochloridedrug
Given orally
placeboother
Given orally